Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib

被引:12
作者
Kim, Myung Soo [1 ]
Chung, Ho Seok [1 ]
Hwang, Eu Chang [1 ]
Jung, Seung Il [1 ]
Kwon, Dong Deuk [1 ]
Hwang, Jun Eul [2 ]
Bae, Woo Kyun [2 ]
Park, Jae Young [3 ]
Jeong, Chang Wook [4 ]
Kwak, Cheol [4 ]
Song, Cheryn [5 ]
Seo, Seong Il [6 ]
Byun, Seok-Soo [7 ]
Hong, Sung-Hoo [8 ]
Chung, Jinsoo [9 ]
机构
[1] Chonnam Natl Univ, Med Sch, Chonnam Natl Univ Hwasun Hosp, Dept Urol, 322 Seoyang Ro, Hwasun 58128, South Korea
[2] Chonnam Natl Univ, Med Sch, Chonnam Natl Univ Hwasun Hosp, Dept Hematooncol, 322 Seoyang Ro, Hwasun 58128, South Korea
[3] Korea Univ, Dept Urol, Ansan Hosp, Ansan, South Korea
[4] Seoul Natl Univ Hosp, Dept Urol, Seoul, South Korea
[5] Asan Med Ctr, Dept Urol, Seoul, South Korea
[6] Sungkyunkwan Univ, Samsung Med Ctr, Dept Urol, Sch Med, Seoul, South Korea
[7] Seoul Natl Univ, Dept Urol, Bundang Hosp, Seongnam, South Korea
[8] Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul, South Korea
[9] Natl Canc Ctr, Dept Urol, Goyang, South Korea
关键词
Renal Cell Carcinoma; Neoplasm Metastasis; Sunitinib; Pazopanib; PROGNOSTIC-FACTORS; SURVIVAL; OUTCOMES; BONE; TRIAL;
D O I
10.3346/jkms.2018.33.e325
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice. Methods: Data of 554 patients with mRCC who received SU or PZ at eight institutions between 2012 and 2016 were retrospectively reviewed. Based on the targeted therapy, the patients were divided into SU (n = 293) or PZ (n = 261) groups, and the clinicopathological variables and survival rates of the two groups were compared. A multivariable Cox proportional hazard model was used to determine the prognostic factors for OS. Results: The median follow-up was 16.4 months (interquartile range, 8.3-31.3). Patients in the PZ group were older, and no significant difference was observed in the performance status (PS) between the two groups. In the SU group, the dose reduction rate was higher and the incidence of grade 3 toxicity was more frequent. The objective response rates were comparable between the two groups (SU, 32.1% vs. PZ, 36.4%). OS did not differ significantly between the two groups (SU, 36.5 months vs. PZ, 40.2 months; log-rank, P= 0.955). Body mass index, Eastern Cooperative Oncology Group PS > 2, synchronous metastasis, poor Heng risk criteria, and liver and bone metastases were associated with a shorter OS. Conclusion: Our real-world data of Korean patients with mRCC suggested that SU and PZ had similar efficacies as first-line therapy for mRCC. However, PZ was better tolerated than SU in Korean patients.
引用
收藏
页数:10
相关论文
共 28 条
[1]   Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations [J].
Albiges, Laurence ;
Hakimi, A. Ari ;
Xie, Wanling ;
McKay, Rana R. ;
Simantov, Ronit ;
Lin, Xun ;
Lee, Jae-Lyun ;
Rini, Brian I. ;
Srinivas, Sandy ;
Bjarnason, Georg A. ;
Ernst, Scott ;
Wood, Lori A. ;
Vaishamayan, Ulka N. ;
Rha, Sun-Young ;
Agarwal, Neeraj ;
Yuasa, Takeshi ;
Pal, Sumanta K. ;
Bamias, Aristotelis ;
Zabor, Emily C. ;
Skanderup, Anders J. ;
Furberg, Helena ;
Fay, Andre P. ;
de Velasco, Guillermo ;
Preston, Mark A. ;
Wilson, Kathryn M. ;
Cho, Eunyoung ;
McDermott, David F. ;
Signoretti, Sabina ;
Heng, Daniel Y. C. ;
Choueiri, Toni K. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (30) :3655-+
[2]   Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules [J].
Atkinson, Bradley J. ;
Kalra, Sarathi ;
Wang, Xuemei ;
Bathala, Tharakeswara ;
Corn, Paul ;
Tannir, Nizar M. ;
Jonasch, Eric .
JOURNAL OF UROLOGY, 2014, 191 (03) :611-618
[3]   Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study [J].
Buti, Sebastiano ;
Donini, Maddalena ;
Bersanelli, Melissa ;
Gattara, Alessia ;
Leonardi, Francesco ;
Passalacqua, Rodolfo .
DRUGS IN R&D, 2017, 17 (04) :585-596
[4]   Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study [J].
Escudier, Bernard ;
Porta, Camillo ;
Bono, Petri ;
Powles, Thomas ;
Eisen, Tim ;
Sternberg, Cora N. ;
Gschwend, Juergen E. ;
De Giorgi, Ugo ;
Parikh, Omi ;
Hawkins, Robert ;
Sevin, Emmanuel ;
Negrier, Sylvie ;
Khan, Sadya ;
Diaz, Jose ;
Redhu, Suman ;
Mehmud, Faisal ;
Cella, David .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (14) :1412-+
[5]   Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing [J].
Gerlinger, Marco ;
Rowan, Andrew J. ;
Horswell, Stuart ;
Larkin, James ;
Endesfelder, David ;
Gronroos, Eva ;
Martinez, Pierre ;
Matthews, Nicholas ;
Stewart, Aengus ;
Tarpey, Patrick ;
Varela, Ignacio ;
Phillimore, Benjamin ;
Begum, Sharmin ;
McDonald, Neil Q. ;
Butler, Adam ;
Jones, David ;
Raine, Keiran ;
Latimer, Calli ;
Santos, Claudio R. ;
Nohadani, Mahrokh ;
Eklund, Aron C. ;
Spencer-Dene, Bradley ;
Clark, Graham ;
Pickering, Lisa ;
Stamp, Gordon ;
Gore, Martin ;
Szallasi, Zoltan ;
Downward, Julian ;
Futreal, P. Andrew ;
Swanton, Charles .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) :883-892
[6]   Rising incidence of small renal masses: A need to reassess treatment effect [J].
Hollingsworth, John M. ;
Miller, David C. ;
Daignault, Stephanie ;
Hollenbeck, Brent K. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (18) :1331-1334
[7]   A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients [J].
Houk, Brett E. ;
Bello, Carlo L. ;
Kang, Dongwoo ;
Amantea, Michael .
CLINICAL CANCER RESEARCH, 2009, 15 (07) :2497-2506
[8]   Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer [J].
Iacovelli, Roberto ;
Rocca, Maria Cossu ;
Galli, Luca ;
De Giorgi, Ugo ;
Sabbatini, Roberto ;
Santoni, Matteo ;
Mosca, Alessandra ;
Fornarini, Giuseppe ;
Massari, Francesco ;
Masini, Cristina ;
Bersanelli, Melissa ;
Biasco, Elisa ;
Lolli, Cristian ;
Guida, Annalisa ;
Berardi, Rossana ;
Terrone, Carlo ;
Pastorino, Alessandro ;
Ardizzoni, Andrea ;
Pinto, Carmine ;
Buti, Sebastiano ;
Nole, Franco ;
Tortora, Giampaolo .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (09) :541.e7-541.e13
[9]   Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease [J].
Janzen, NK ;
Kim, HL ;
Figlin, RA ;
Belldegrun, AS .
UROLOGIC CLINICS OF NORTH AMERICA, 2003, 30 (04) :843-+
[10]   Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era [J].
Kalra, Sarathi ;
Verma, Jonathan ;
Atkinson, Bradley J. ;
Matin, Surena F. ;
Wood, Christopher G. ;
Karam, Jose A. ;
Lin, Sue-Hwa ;
Satcher, Robert L. ;
Tamboli, Pheroze ;
Sircar, Kanishka ;
Rao, Priya ;
Corn, Paul G. ;
Tannir, Nizar M. ;
Jonasch, Eric .
CLINICAL GENITOURINARY CANCER, 2017, 15 (03) :363-370